Li, Anlin
Luo, Linfeng
Du, Wei
Yu, Zhixin
He, Lina
Fu, Sha
Wang, Yuanyuan
Zhou, Yixin
Yang, Chunlong
Yang, Yunpeng
Fang, Wenfeng
Zhang, Li
Hong, Shaodong http://orcid.org/0000-0002-5632-6857
Funding for this research was provided by:
National Natural Science Foundation of China (81972898 and 82172713)
Article History
Received: 28 February 2023
Accepted: 31 August 2023
First Online: 11 September 2023
Competing interests
: The authors declare no competing interests.
: For this study, ethical approval has been obtained by the institutional review board of Sun Yat-sen University Cancer Center (SL-B2020-402-02). For OAK, POPLAR, and IMvigor210 trials, the protocol has been approved by each local ethics committee, and all participants provided written informed consent. These trials were done in accordance with the Declaration of Helsinki.